Recent advances in idiopathic pulmonary fibrosis

Park S.; Lee E.J.

doi:10.4046/trd.2013.74.1.1

상세 보기

Recent advances in idiopathic pulmonary fibrosis

Park S.;
Lee E.J.

Citations

SCOPUS

21

초록

The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright©2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

키워드

Clinical trial; Etiology; Idiopathic pulmonary fibrosis; acetylcysteine; azathioprine; bosentan; gelatinase A; gelatinase B; interstitial collagenase; losartan; matrilysin; neutrophil collagenase; nintedanib; pirfenidone; placebo; prednisone; thalidomide; warfarin; aging; airway remodeling; aminotransferase blood level; angiogenesis; cell differentiation; coughing; drug efficacy; drug withdrawal; exploratory research; fibrosing alveolitis; forced vital capacity; gastrointestinal symptom; genotype environment interaction; human; lung alveolus cell type 1; lung alveolus epithelium; lung injury; mesothelium cell; monotherapy; myofibroblast; pericyte; phase 3 clinical trial (topic); pilot study; randomized controlled trial (topic); review; side effect; treatment withdrawal

제목: Recent advances in idiopathic pulmonary fibrosis

저자: Park S.; Lee E.J.

DOI: 10.4046/trd.2013.74.1.1

발행일: 2013

유형: Review

저널명: Tuberculosis and Respiratory Diseases

권: 74

호: 1

페이지: 1 ~ 6

언어: ENG

출판사: 대한결핵및호흡기학회

발행국가: 대한민국

분량: 6 페이지

ISSN: E 2005-6184
P 1738-3536